Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
-
- Yongsheng Wang
- Shanghai Pulmonary Hospital, Cancer Institute, School of Medicine, Tongji University, Shanghai, PR China
-
- Gerald Schmid-Bindert
- Interdisciplinary Thoracic Oncology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
-
- Caicun Zhou
- Shanghai Pulmonary Hospital, Cancer Institute, School of Medicine, Tongji University, Shanghai 200433, PR China
説明
<jats:p> Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of the EGFR, were approved in many countries for the treatment of locally advanced or metastatic NSCLC as a second- or third-line regimen. Since then, randomized trials have evaluated the role of these two targeted agents alone or combined with chemotherapy in maintenance and first-line settings. This review summarizes the results of recent clinical trials with these tyrosine kinase inhibitors, with a focus on erlotinib, as first-line treatment towards a form of personalized medicine aimed at improving clinical outcome in advanced NSCLC. </jats:p>
収録刊行物
-
- Therapeutic Advances in Medical Oncology
-
Therapeutic Advances in Medical Oncology 4 (1), 19-29, 2011-11-07
SAGE Publications